Exact Sciences Corp
EXAS46.800USD
-0.740-1.56%
Handelsschluss 07/30, 16:00（ET）Kurse um 15 Minuten verzögert
8.83BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Exact Sciences Corp Unternehmen
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Unternehmensinformationen
BörsenkürzelEXAS
Name des UnternehmensExact Sciences Corp
IPO-datumJan 30, 2001
Gegründet am1995
CEOMr. Kevin T. Conroy
Anzahl der mitarbeiter6900
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
Addresse5505 Endeavor Lane
StadtMADISON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl53719
Telefon16082845700
Websitehttps://www.exactsciences.com/
BörsenkürzelEXAS
IPO-datumJan 30, 2001
Gegründet am1995
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
72.76K
+3.10%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.26K
+0.94%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
16.38K
+156.47%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Mr. Michael J. (Mike) Barber, M.D.
Mr. Michael J. (Mike) Barber, M.D.
Independent Director
Independent Director
13.14K
+121.18%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
72.76K
+3.10%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.26K
+0.94%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Commercial
332.50M
47.04%
Medicare Parts B & C
247.89M
35.07%
Other
74.81M
10.58%
International
51.59M
7.30%
Nach RegionUSD
Name
Umsatz
Anteil
United States (Country)
655.20M
92.70%
Outside of united states
51.59M
7.30%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Commercial
332.50M
47.04%
Medicare Parts B & C
247.89M
35.07%
Other
74.81M
10.58%
International
51.59M
7.30%
Aktionärsstatistik
Aktualisiert: Wed, Jul 23
Aktualisiert: Wed, Jul 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
12.80%
Capital World Investors
9.45%
The Vanguard Group, Inc.
9.31%
Wellington Management Company, LLP
6.63%
BlackRock Institutional Trust Company, N.A.
4.07%
Other
57.74%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
12.80%
Capital World Investors
9.45%
The Vanguard Group, Inc.
9.31%
Wellington Management Company, LLP
6.63%
BlackRock Institutional Trust Company, N.A.
4.07%
Other
57.74%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
60.76%
Investment Advisor/Hedge Fund
27.66%
Hedge Fund
4.36%
Research Firm
2.48%
Bank and Trust
1.36%
Pension Fund
1.14%
Individual Investor
0.92%
Sovereign Wealth Fund
0.54%
Private Equity
0.36%
Other
0.41%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1379
202.06M
107.12%
+2.47M
2025Q1
1424
199.78M
106.03%
-445.52K
2024Q4
1411
200.72M
108.09%
-225.66K
2024Q3
1375
190.82M
103.28%
-5.17M
2024Q2
1358
185.25M
100.40%
+6.59M
2024Q1
1347
168.41M
92.78%
-6.10M
2023Q4
1356
165.31M
91.41%
-11.01M
2023Q3
1337
167.70M
92.83%
-6.22M
2023Q2
1354
166.38M
92.24%
-10.65M
2023Q1
1343
167.01M
92.90%
-8.56M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
24.14M
12.8%
+5.29M
+28.03%
Mar 31, 2025
Capital World Investors
17.84M
9.45%
+297.66K
+1.70%
Mar 31, 2025
The Vanguard Group, Inc.
17.56M
9.31%
+616.59K
+3.64%
Mar 31, 2025
Wellington Management Company, LLP
12.50M
6.63%
+442.78K
+3.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.68M
4.07%
+12.62K
+0.16%
Mar 31, 2025
State Street Global Advisors (US)
6.61M
3.51%
+381.12K
+6.11%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.25M
3.32%
+631.23K
+11.22%
Mar 31, 2025
Fidelity Institutional Asset Management
3.59M
1.9%
+1.68M
+88.60%
Mar 31, 2025
Mackenzie Investments
3.28M
1.74%
+362.31K
+12.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.27M
1.73%
+143.64K
+4.60%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
First Trust NYSE Arca Biotechnology Index Fund
3.97%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.96%
Invesco Biotechnology & Genome ETF
3.25%
SPDR S&P Biotech ETF
2.41%
First Trust Indxx Medical Devices ETF
2.39%
Capital Group US Small and Mid Cap ETF
2.22%
Franklin Genomic Advancements ETF
2.18%
Nuveen ESG Mid-Cap Growth ETF
2.09%
iShares Health Innovation Active ETF
2.07%
ROBO Global Healthcare Technology & Innovation ETF
1.97%
Mehr Anzeigen
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.97%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil3.96%
Invesco Biotechnology & Genome ETF
Anteil3.25%
SPDR S&P Biotech ETF
Anteil2.41%
First Trust Indxx Medical Devices ETF
Anteil2.39%
Capital Group US Small and Mid Cap ETF
Anteil2.22%
Franklin Genomic Advancements ETF
Anteil2.18%
Nuveen ESG Mid-Cap Growth ETF
Anteil2.09%
iShares Health Innovation Active ETF
Anteil2.07%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.97%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
